Miniatura

Fitxers

227559.pdf (770.32 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2020-08-15

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/218070

The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/ijc.32865

Resum

Around 40% of newly diagnosed lung cancer patients are Stage IV, where the improvement of survival and reduction of disease-related adverse events is the main goal for oncologists. In this scenario, we present preclinical evidence supporting the use of ABTL0812 in combination with chemotherapy for treating advanced and metastatic Nonsmall cell lung adenocarcinomas (NSCLC) and squamous carcinomas. ABTL0812 is a new chemical entity, currently in Phase 1b/2a clinical trial for advanced squamous NSCLC in combination with paclitaxel and carboplatin (P/C), after successfully completing the first-in-human trial where it showed an excellent safety profile and signs of efficacy. We show here that ABTL0812 inhibits Akt/mTOR axis by inducing the overexpression of TRIB3 and activating autophagy in lung squamous carcinoma cell lines. Furthermore, treatment with ABTL0812 also induces AMPK activation and ROS accumulation. Moreover, combination of ABTL0812 with chemotherapy markedly increases the therapeutic effect of chemotherapy without increasing toxicity. We further show that combination of ABTL0812 and chemotherapy induces nonapoptotic cell death mediated by TRIB3 activation and autophagy induction. We also present preliminary clinical data indicating that TRIB3 could serve as a potential novel pharmacodynamic biomarker to monitor ABTL0812 activity administered alone or in combination with chemotherapy in squamous NSCLC patients. The safety profile of ABTL0812 and its good synergy with chemotherapy potentiate the therapeutic potential of current lines of treatment based on chemotherapy regimens, arising as a promising option for improving these patients therapeutic expectancy.

Matèries

Administració de medicaments, Proteïnes, Quimioteràpia, Autofàgia, Càncer de pulmó

Matèries (anglès)

Administration of drugs, Proteins, Chemotherapy, Autophagy, Lung cancer

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)

Citació

LÓPEZ PLANA, Anna, FERNÁNDEZ NOGUEIRA, Patricia, MUÑOZ GUARDIOLA, Pau, SOLÉ SÁNCHEZ, Sònia, MEGÍAS RODA, Elisabet, PÉREZ-MONTOYO, Hector, JAUREGUI, Patricia, YESTE VELASCO, Marc, GÓMEZ FERRERIA, Mariana, ERAZO, Tatiana, AMETLLER, Elisabet, RECALDE PERCAZ, Leire, MORAGAS GARCIA, Núria, NOGUERA CASTELLS, Aleix, MANCINO, Mario, MORÁN, Teresa, NADAL, Ernest, ALFÓN, José, DOMÈNECH, Carles, GASCON, Pere, LIZCANO, José miguel, FUSTER ORELLANA, Gemma, BRAGADO DOMINGO, Paloma. The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.. _International Journal of Cancer_. 2020. Vol. 147, núm. 4, pàgs. 1163-1179. [consulta: 22 de gener de 2026]. ISSN: 0020-7136. [Disponible a: https://hdl.handle.net/2445/218070]

Exportar metadades

JSON - METS

Compartir registre